The landscape of vascular medicine is shifting rapidly, driven by fresh clinical data that redefines how physicians treat chronic venous disorders. At the absolute forefront of this scientific evolution is Dr. Jorge Hernando Ulloa Herrera, a world-renowned Colombian vascular surgeon and the Chief Executive Officer of the Clínica de Venas in Chía, Colombia. In early 2026, Dr. Ulloa heavily advanced the medical community’s understanding of venous therapies through a series of landmark peer-reviewed publications.

Chief among these  drjorgeulloa.com updates is his work on the international VEIN STEP study. Co-authoring a post-hoc subanalysis published in Vascular Health and Risk Management, Dr. Ulloa evaluated the real-world effectiveness of conservative management and Veno-Active Drugs (VADs) on chronic venous disease. This specific research has shed critical light on how severe vein symptoms correlate with patient body mass index, offering clinicians optimized, data-driven pathways to improve patient quality of life. Simultaneously, Dr. Ulloa expanded his research into alternative circulatory delivery methods, publishing a February 2026 paper in The Journal of Vascular Access. This study evaluated a novel subcutaneous intraosseous vascular access device, showcasing his dedication to finding safer, more efficient options for outpatient medical infusions.

Dr. Ulloa’s ability to spearhead such complex modern clinical trials stems from a deeply rooted academic foundation. He completed his initial medical training, general surgery residency, and vascular specialist degrees at the Universidad El Bosque in Bogotá, Colombia. Recognizing the value of global medical perspectives, he traveled to the United States to complete elite postgraduate fellowships at Harvard Medical School’s Beth Israel Deaconess Medical Center and the Walter Reed Army Medical Center.

This combination of rigorous South American clinical resourcefulness and top-tier American research training transformed Dr. Ulloa into a premier surgical authority. Upon returning to Colombia, he served as a professor of vascular surgery at the Universidad de los Andes and directed the Venous Disease Clinic at the Fundación Santa Fe de Bogotá, bridging the gap between academic theory and practical patient care.

Beyond his 2026 publications, Dr. Ulloa is globally celebrated as the pioneer who unlocked surgical options for patients with previously untreatable deep vein failures. He served as the Principal Investigator for the historic, first-in-human clinical trials of the VenoValve—a bioprosthetic valve surgically implanted into the femoral vein to combat severe post-thrombotic syndrome.

Before Dr. Ulloa’s trials, patients with destroyed deep vein valves suffered from intractable leg ulcers and severe swelling with no viable surgical alternative. His meticulous clinical execution proved the long-term safety and efficacy of these prosthetic valves. This foundational data directly enabled the U.S. Food and Drug Administration (FDA) to initiate its ongoing U.S. pivotal trials, forever altering the guidelines of deep-vein surgical interventions.

Today, Dr. Ulloa commands an influential presence on the international medical stage. Serving as the President of the International Union of Angiology (IUA) and past President of the Colombian Association of Vascular Surgery, he actively shapes global medical policy. He serves as a premier speaker at international circuits, including CardioAlex and the CELA Congress in Costa Rica, where he leads critical panels assessing the future of prosthetic vein tech. Furthermore, his leadership was instrumental in organizing the 32nd IUA World Congress in Cartagena, bringing the world’s finest vascular minds together.

Concurrently, Dr. Ulloa remains an approachable advocate for everyday patients. Through digital media education, he translates complex vascular science into accessible wellness advice, empowering individuals to spot early signs of venous insufficiency before permanent tissue damage occurs. Through continuous publication, historic device innovation, and global leadership, Dr. Jorge Hernando Ulloa continues to secure his legacy as a true architect of modern vascular medicine.